De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten
Publication date
2019-12-01
Authors
Wegelin, O.
Exterkate, L.
Barentsz, J. O.
van der Leest, M. G.
Kelder, J. C.
Kummer, J. A.
Vreuls, W.
de Bruin, P. C.
de Vocht, T. F.
Nuininga, J. E.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
The FUTURE trial is a multicenter RCT on 3 MRI-based target biopsy (TB) techniques among patients with negative systematic biopsies (SBs) and persisting suspicion of prostate cancer. Between 2014 and 2017 665 patients underwent multiparametric MRI. 234 (35%) patients with a PIRADS ≥3 lesion were randomised 1:1:1 for TB: in-bore MRI (MRI-TB), MRI/ultrasound fusion (FUS-TB), and cognitive fusion (COG-TB). After FUS-TB and COG-TB additional SB was performed. No significant differences in prostate cancer detection and significant prostate cancer were found (MRI-TB 54.5%/32.5%, FUS-TB 49.4%/34.2%, and COG-TB 43.6%/33.3%, p = 0.39/p = 0.98). Combined SBs and TBs versus TBs alone resulted in 1% more csPCa detection (35% vs 34%). There was no significant advantage of one TB technique for the detection of overall prostate cancer, nor for clinically significant prostate cancer. The additional value of SBs was limited.
Keywords
biopsy, diagnosis, MRI, prostate cancer, Urology
Citation
Wegelin, O, Exterkate, L, Barentsz, J O, van der Leest, M G, Kelder, J C, Kummer, J A, Vreuls, W, de Bruin, P C, de Vocht, T F, Nuininga, J E, Bosch, J L H R, Somford, D M & van Melick, H H E 2019, 'De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten : Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten', Tijdschrift voor Urologie, vol. 9, no. 8, pp. 146-156. https://doi.org/10.1007/s13629-019-0252-9